Non-Hodgkin Lymphoma | Specialty

Relapsed/Refractory CLL Treatment: Addressing Unmet Needs

February 8th 2021

FDA Approves Umbralisib for Marginal Zone Lymphoma, Follicular Lymphoma

February 5th 2021

February 5, 2021 - The FDA has granted an accelerated approval to umbralisib for the treatment of select patients with relapsed/refractory marginal zone lymphoma and relapsed/refractory follicular lymphoma.

FDA Approves Liso-Cel for Refractory Large B-Cell Lymphoma

February 5th 2021

February 5, 2021 - The FDA has approved lisocabtagene maraleucel for the treatment of adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least 2 other types of systemic treatment.

R/R DLBCL: Second-Line Treatment Options

February 5th 2021

DLBCL: Treating Patients Following Relapse on Frontline Therapy

February 5th 2021

Selinexor Approved in Israel for Multiple Myeloma, DLBCL

February 4th 2021

February 4, 2021 — The Israeli Ministry of Health has approved selinexor for the treatment of patients with multiple myeloma or diffuse large B-cell lymphoma.

2020 Approvals Expand Access to Care for Patients Across Tumor Types

February 4th 2021

In a year marked by collaboration and innovation, therapeutic developments in oncology care once again dominated the novel drug approvals in 2020.

Surge of New Drugs Fuels Optimism in Pediatric Oncology

February 4th 2021

The landscape for pediatric oncology drugs expanded dramatically last year, with 8 new drugs or indications specifically approved for children compared with just 47 for treatment and supportive care products from the early 1950s through 2019.

DPX-Survivac/Cyclophosphamide Plus Pembrolizumab Shows Early Promise in Relapsed/Refractory DLBCL

February 3rd 2021

Neil Berinstein, MD, discussed the early promise with this T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

A Look at the ELEVATE-TN and ASCEND Trials

February 3rd 2021

Dr Stilgenbauer explains the ELEVATE-TN and ASCEND clinical trials; Dr Brown highlights the adverse effects seen with acalabrutinib.

Acalabrutinib in the Treatment of Chronic Lymphocytic Leukemia

February 3rd 2021

Experts provide insight on the use of acalabrutinib in treating chronic lymphocytic leukemia.

Clinical Trials With BTK Inhibitors in Chronic Lymphocytic Leukemia

February 3rd 2021

Dr Brown provides a brief overview of data available that support the use of Bruton’s tyrosine kinase inhibitors in treating chronic lymphocytic leukemia; Dr Stilgenbauer comments on mitigating and managing adverse effects in the treatment of chronic lymphocytic leukemia.

BTK Inhibitors in Treatment of Chronic Lymphocytic Leukemia

February 3rd 2021

Dr Ghia provides an in-depth conversation on the use of Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia.

DLBCL: Treatment Considerations for Challenging Populations

January 29th 2021

DLBCL: Circumstances for Deviating Away From R-CHOP

January 29th 2021

Rapid Readouts: Phase 1/2 Study of Epcoritamab in R/R B-cell NHL

January 28th 2021

BTK Combos Seek to Raise the Bar in CLL Treatment Paradigm

January 27th 2021

Tara Graff, DO, highlights active areas of exploration that are generating excitement in chronic lymphocytic leukemia.

Acalabrutinib Shows Noninferior PFS, Less Atrial Fibrillation Versus Ibrutinib in High-Risk CLL

January 26th 2021

January 26, 2021 - Acalabrutinib showed noninferior progression-free survival and a significantly lower incidence of atrial fibrillation versus ibrutinib in patients with high-risk chronic lymphocytic leukemia.

Rapid Readouts: Phase 2 JULIET Trial

January 26th 2021

Acalabrutinib Approved in Japan for Relapsed/Refractory CLL

January 25th 2021

January 25, 2021 - The Japanese Ministry of Health, Labour and Welfare approved the BTK inhibitor acalabrutinib for use in adult patients with relapsed/refractory chronic lymphocytic leukemia, including small lymphocytic lymphoma